Pentagon contract could send this $2 AI stock soaring

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

John S. Montalbano net worth and biography

John Montalbano Biography and Net Worth

Director of AbCellera Biologics

Mr. Montalbano is Principal of Tower Beach Capital Ltd. and serves on the boards of the Canada Pension Plan Investment Board, Aritzia Inc., and the Asia Pacific Foundation of Canada. His previous appointments include the former Vice Chair of RBC Wealth Management and CEO of RBC Global Asset Management (RBC GAM). When Mr. Montalbano retired as CEO of RBC GAM in 2015, it was among the largest 50 asset managers worldwide with $370 billion under management and offices in Canada, the United States, the United Kingdom, and Hong Kong.

Mr. Montalbano holds a Chartered Financial Analyst designation and a Bachelor of Commerce, with Honours, from the University of British Columbia. He is a Leslie Wong Fellow of the UBC Portfolio Management Foundation and holds an Honorary Doctor of Letters from Emily Carr University of Art and Design.

How do I contact John S. Montalbano?: The corporate mailing address for Mr. Montalbano and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on John S. Montalbano's contact information.
Has John S. Montalbano been buying or selling shares of AbCellera Biologics?: John S. Montalbano has not been actively trading shares of AbCellera Biologics during the past quarter. Most recently, on Friday, March 4th, John S. Montalbano bought 10,000 shares of AbCellera Biologics stock. The stock was acquired at an average cost of $8.54 per share, with a total value of $85,400.00. Learn More on John S. Montalbano's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.
Are insiders buying or selling shares of AbCellera Biologics?: During the last year, AbCellera Biologics insiders bought shares 2 times. They purchased a total of 167,500 shares worth more than $1,096,885.00. The most recent insider tranaction occured on May, 26th when CFO Andrew Booth bought 14,500 shares worth more than $99,325.00. Insiders at AbCellera Biologics own 32.5% of the company. Learn More about insider trades at AbCellera Biologics.
Information on this page was last updated on 5/26/2023.

John S. Montalbano Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/4/2022	Buy	10,000	$8.54	$85,400.00
3/1/2022	Buy	20,000	$9.05	$181,000.00
8/16/2021	Buy	6,000	$17.23	$103,380.00

John S. Montalbano Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $4.04

$4.00

$4.31

50 Day Range

MA: $4.68

$3.87

$5.34

2 Week Range

Now: $4.04

$3.79

$8.05

Volume

1,134,495 shs

Average Volume

1,357,708 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36